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Forty patients (33 male, 7 female) with refractory epilepsy were randomized to receive ascending weekly doses of adjunctive
remacemide hydrochloride in a b.i.d. or q.i.d. regimen, or placebo for up to 1 month. Assessments included routine physical
examination and laboratory tests, recording of adverse events and seizure frequency, and neuropsychological tests. Trough
plasma concentrations of concomitant AEDs were measured at weekly intervals. Trough plasma concentrations of remacemide
and its desglycinyl metabolite were measured before each dose increment, and complete 24-hour profiles were measured at
steady state following administration of 600 mg day−1 and 1200 mg day−1.
A daily dose of 1200 mg was well tolerated in a q.i.d. regimen and up to 800 mg was well tolerated in a b.i.d. regimen.
The most common adverse events were dizziness, diplopia, dyspepsia and abdominal pain. On some occasions, these were
considered to be related to raised concentrations of concomitant AEDs. No adverse effects were observed on seizure frequency.
Neuropsychology tests revealed no significant changes. Remacemide and the desglycinyl metabolite demonstrated dose propor-
tional pharmacokinetics over the dose range tested.
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INTRODUCTION
Remacemide hydrochloride and its principal active
desglycinyl metabolite are low-affinity N-methyl-D-
aspartic acid (NMDA) receptor channel blocking
agents with additional significant sodium fast chan-
nel blocking activity1. Non-competitive inhibition of
NMDA receptors located within neuronal membrane
calcium channels is thought to block the Ca2+ in-
flux mediated by major excitatory neurotransmitters,
principally glutamate and glycine. This results in re-
duced cortical neuronal activity and, potentially, sup-
pression of seizures. The anticonvulsant properties of
remacemide hydrochloride have been demonstrated in
a variety of animal models2. Remacemide hydrochlo-
ride may, therefore, represent the first of a new class
of AED.
In a previous study in adult patients with epilepsy3,
remacemide hydrochloride capsules were generally
well tolerated in doses up to 600 mg day−1 in
a q.i.d. regimen. In addition, it was observed that
the metabolism of remacemide hydrochloride was
induced by co-administration of hepatic enzyme-
inducing AEDs such as carbamazepine and pheny-
toin4, 5. Furthermore, remacemide hydrochloride, in
turn, inhibited the metabolism of some of these
enzyme-inducing AEDs.
The purpose of this study was to evaluate the
safety, tolerability and pharmacokinetics of ascend-
ing doses of adjunctive remacemide hydrochloride, in
b.i.d. or q.i.d. regimens, compared with placebo in
adult patients with refractory epilepsy.
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MATERIALS AND METHODS
Trial design, patient inclusion and exclusion
criteria
This was a two-centre, double-blind, randomized,
three-way parallel group comparison of adjunctive
remacemide hydrochloride, administered in b.i.d. or
q.i.d. regimens, and placebo, over 28 days, in patients
with epilepsy. All patients gave written informed con-
sent to participate in the trial and continued to take
a fixed dose of one or two AEDs, including either
carbamazepine or phenytoin, during the study period.
The study was planned for a minimum of 12 patients
per treatment group. A total of 45 patients were re-
cruited at the two centres between 3 January and
27 April 1992, the last patient completing the study
on 25 June 1992.
Reasons for exclusion from the study included a his-
tory of pseudoseizures, a clinically significant medical
condition other than epilepsy, a history of alcohol or
drug abuse, and regular use of antidepressants, tran-
quillizers or non-steroidal anti-inflammatory drugs.
Women of child-bearing potential and patients who
had received an investigational drug within 3 months
prior to screening were also excluded.
Test treatments and assessments
Six tablet formulations of identical appearance were
used in the study: placebo, 50 mg, 100 mg, 150 mg,
200 mg, and 300 mg remacemide (base content). All
treatments were administered in a q.i.d. regimen at
08:00, 12:00, 16:00 and 20:00 hours, with patients in
the remacemide hydrochloride b.i.d. treatment group
receiving placebo each day at 1200 and 1600 hours to
preserve blinding.
Those patients randomized to the adjunctive
remacemide hydrochloride b.i.d. or q.i.d. treatment
groups, initially received a single introductory dose of
200 mg on day one of the study period. Thereafter, an
ascending dose schedule was followed in both groups;
the daily dose was increased after 1 week at each dose
level. Dosage commenced at 400 mg day−1 for the
first week, followed by 600, 800 and 1200 mg day−1
during weeks 2, 3 and 4.
Patients were hospitalized 24 hours prior to receiv-
ing the first increased dose at each phase of the study,
and physical examinations, neurological assessment,
ECG measurement, recording of vital sign, neuropsy-
chological testing, and blood and urine sampling for
laboratory analyses were scheduled at this point. Ad-
verse events, the nature and frequency of seizures
experienced, and compliance to dosage instructions
were recorded at each visit, following patient ques-
tioning and examination of patient diary cards by the
investigators. Patients remained as inpatients for up to
24 hours after the first increased dose was adminis-
tered, in each weekly phase.
Those patients who, in the opinion of the investiga-
tor, showed intolerance to remacemide hydrochloride
during weeks 2–4 were down-titrated to a lower dose
and continued at the reduced dose for the remaining
study period. Any patient intolerant of the lowest dose
of remacemide hydrochloride was withdrawn from the
study. At the end of 4 weeks, remacemide hydrochlo-
ride treated patients were gradually withdrawn from
the drug over a six-day period.
Pharmacokinetic objectives for the study were to
measure the steady-state trough plasma concentrations
of remacemide and the desglycinyl metabolite at each
dose level, and to examine the plasma profiles over
12 hours at the 600 mg day−1 dose, and at the end of
the highest dose used. Comparisons between the b.i.d.
and q.i.d. dosing regimens could then be made. Con-
comitant AED plasma concentrations (carbamazepine
and phenytoin) were monitored throughout the study.
Patients recorded their medication usage, adverse
events and seizures on diary cards throughout the
study. Seizures were classified according to the In-
ternational Seizure Classification of Epilepsy as sim-
ple partial, complex partial, secondary generalized and
primary generalized tonic–clonic seizures.
At screening, a physical and neurological exami-
nation was carried out, together with an ECG and
vital signs measurements, and neuropsychological
tests were performed. The neuropsychological tests
comprised finger tapping, stroop and digit cancel-
lation, digit span and logical memory, list learn-
ing, design recall and design learning. In addition,
blood samples were taken for clinical laboratory tests
and plasma concentrations of remacemide, the desg-
lycinyl metabolite and concomitant AEDs. These mea-
surements were repeated at periodic intervals during
the study. At each study visit, adverse events were
recorded following examination of the diary card and
direct questioning of the patient. Compliance was as-
sessed by examining the diary card, by patient ques-
tioning, and by tablet counts.
Any patient who withdrew from the study due to an
adverse event was followed up until the event had re-
solved and any relationship to the study treatment was
established.
Statistical methods
Both parametric (analysis of variance) and non-
parametric (Kruskal–Wallis test) statistical methods
were used to analyse data from the three treat-
ment groups. All statistical tests were two-tailed and
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Table 1: Baseline patient demographics and seizure history.
Patient details Remacemide Remacemide Placebo group:
HCl b.i.d.: n = 13 HCl q.i.d.: n = 13 n = 14
Age (years) Mean 36.3 36.2 40.4
Range 20–53 22–60 23–66
Sex Male 9 12 12
Female 4 1 2
Duration of Mean 23.5 22.2 21.9
epilepsy (years) Range 4–41 4–40 4–54
Types of seizure experienced:
• Simple partial 8 4 4
• Complex partial 10 10 12
• Secondary generalized 8 8 9
• Primary generalized 1 1 2
Number of seizures during Mean 5.1 2.8 7.8
baseline 7 day period Range 0–17 0–17 0–62
Table 2: Summary of patient withdrawals.
Treatment group Days on treatment Dose at time Reason for withdrawal Relationship to
of withdrawal test treatment
Remacemide
hydrochloride b.i.d.
16 800 mg day−1 Intercurrent illness; patient choked on
food and required hospitalization
Unlikely
Remacemide
hydrochloride b.i.d.
18 400 mg day−1 Nausea despite dose
reduction
Possible
Remacemide
hydrochloride q.i.d.
1 400 mg day−1 Low neutrophil count prior to receiving
test treatment
None
Placebo 5 Placebo Deterioration in epilepsy status Unlikely
carried out to determine statistical significance at the
5% level. The three treatment groups were compared
at baseline and at subsequent timepoints using the
Mack–Skillings statistic6 to adjust for centre differ-
ences. Where an overall significant difference between
treatment groups was established, pairwise compar-
isons of the three treatment groups were performed
using Mann–Whitney U -tests.
RESULTS
Patient entry, exposure and concomitant
medications
Forty patients were randomized to receive test medi-
cation. The summary demographic profile and seizure
history for patients randomized to each treatment
group is presented in Table 1.
The treatment groups were comparable with respect
to demographic data, seizure type and concomitant
AEDs. All patients were receiving other AEDs dur-
ing the study; these comprised carbamazepine (29
patients), phenytoin (17), valproate (8), vigabatrin (8),
clobazam (6), lamotrigine (4), phenobarbital (3) and
primidone (1).
Safety analyses
Withdrawals, dose adjustments and compliance
Four patients were withdrawn from the study; three
were receiving remacemide hydrochloride, and one
patient was in the placebo group. Details are summa-
rized in Table 2.
Compliance with the test treatments was generally
good. Sixteen patients who received remacemide hy-
drochloride and 12 patients who received placebo
completed the study and received all the dose in-
crements as specified in the protocol (Table 3).
Seven patients treated with remacemide hydrochloride
(five b.i.d., two q.i.d.) required dose adjustments due
to intolerance during the study. Of these, two patients
were reduced from 1200 to 800 mg day−1 in the b.i.d.
treatment group and four patients were reduced from
800 to 600 mg day−1 (two b.i.d., two q.i.d.). A fur-
ther patient in the b.i.d. treatment group was reduced
from 800 to 400 mg day−1. One patient remained on
remacemide hydrochloride at 600 mg day−1 in the
b.i.d. treatment group to the end of the study period
due to intolerance beyond this dose. There were no
major protocol violations.
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Table 3: Flow chart showing progress of patients through the
study.
Number of patients
entered in study
45
Number of patients
excluded prior to
randomization
5
Total number of patients
randomized to test
treatment
40
Remacemide hydrochloride Placebo
b.i.d. q.i.d.
Number of patients
randomized to each
treatment group
13 13 14
Number of patients
withdrawn
2 1 1
Number of patients
completing study
(receiving all doses)
6 10 12
Number of patients
completing study (but on
reduced dose)
5 2 1
Adverse events
Thirty eight patients (25 remacemide hydrochloride,
13 placebo) experienced adverse events during the
study. The most commonly reported adverse events
associated with remacemide hydrochloride were
dizziness, ataxia, fatigue, diplopia, abnormal vision,
abdominal pain and dyspepsia. The adverse events
experienced by 10% or more of patients are listed in
Table 4.
There were seven serious adverse events; five
of these were experienced by patients treated with
remacemide hydrochloride and two by patients in the
placebo treatment group. These events resulted in hos-
pital admission or in extension of hospitalization. Two
of these events were considered by the investigator
to be possibly related to study treatment; one patient
in the remacemide hydrochloride q.i.d. group experi-
enced tonic–clonic seizures 2 days after completing
the treatment phase of the study and one patient in the
placebo group experienced severe vomiting followed
by status epilepticus. The other serious adverse events
were hospitalization for physical injury following a
seizure (1), post-ictal drowsiness (1), dysphagia (1)
and worsening seizures (2).
Laboratory analyses: haematology, biochemistry and
urinalysis
A high proportion of patients (15 remacemide hy-
drochloride and nine placebo) entered the study with
abnormal haematological parameters, notably haema-
tocrit and red cell count outside the normal range.
These values may have been affected by pre-existing
and concomitant carbamazepine treatment. No further
clinically significant changes in these parameters oc-
curred during the study.
Most patients entered the study with high plasma
gamma glutamyl transpeptidase (GGT) due to pre-
existing AED medication. These concentrations re-
mained elevated, although no clinically significant
changes from these baseline concentrations were ob-
served during the study. Similarly, 50% of patients en-
tered the study with elevated plasma cholesterol con-
centrations; these remained elevated throughout the
study but showed no clinically significant changes
from baseline throughout the study. There were in-
creases from baseline in mean alanine amino trans-
ferase (ALT) concentrations in the remacemide hy-
drochloride treated patients of 2.9±4.8 IU l−1 whereas
in the placebo group there was a decrease in mean
ALT concentrations. This difference in the treatment
groups was statistically significant (P = 0.019). In
one patient the increase was considered clinically sig-
nificant but it was attributed by the investigator to con-
comitant medication.
With the exception of one patient diagnosed with
maturity onset diabetes who had marked glycosuria,
urinalysis changes following the test treatments were
unremarkable.
Neuropsychological tests and neurological
examination
No consistent or significant effects on neuropsycho-
logical function attributable to remacemide hydrochlo-
ride or placebo treatment were detected.
Nine patients (five, remacemide hydrochloride, four
placebo) entered the study with nystagmus which con-
tinued throughout the study period. Otherwise, no con-
sistent neurological changes of clinical significance
were observed in the patient population.
Physical examination and vital signs
No clinically significant changes were detected dur-
ing weekly and follow-up physical examinations in
any of the patients in the study. Additionally, no clin-
ically significant differences were seen in vital signs
among the three treatment groups following dosing
and throughout the study.
Pharmacokinetic data
Remacemide and desglycinyl metabolite
A reasonable degree of dose proportionality for
remacemide and the desglycinyl metabolite was
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Table 4: Summary of numbers of patients experiencing the most common (≥10%) adverse events.
Preferred term Remacemide hydrochloride Placebo:
b.i.d.: n = 13 q.i.d.: n = 13 b.i.d. and q.i.d.: n = 26 n = 14
Hypoaesthesia 1 1 2 (7.7) 2 (14.3)
Impaired concentration 0 2 2 (7.7) 3 (21.4)
Vomiting 4 0 4 (11.5) 2 (14.3)
Ataxia 2 2 4 (15.4) 0
Abnormal vision 2 3 5 (19.2) 1 (7.1)
Somnolence 1 5 6 (23.1) 5 (35.7)
Dyspepsia 3 5 8 (30.7) 1 (7.1)
Fatigue 3 5 8 (30.7) 2 (14.3)
Diplopia 4 4 8 (30.7) 2 (14.3)
Abdominal pain 6 4 10 (34.6) 3 (7.1)
Headache 7 6 13 (30.7) 7 (50)
Dizziness 8 6 14 (46.2) 3 (21.4)
apparent for area under the plasma concentration time
curve over the dosing interval (AUCτ ) after both b.i.d.
and q.i.d. dosing. Details are summarized in Table 5.
Table 5: AUCτ determination for remacemide and desglycinyl
metabolite.
Remacemide hydrochloride Mean and (SD) of AUCτ (ng h ml−1)
dose regimen Remacemide Desglycinyl metabolite
300 mg b.i.d. (n = 11) 2028 (808) 427 (270)
600 mg b.i.d. (n = 5) 4880 (1941) 701 (229)
150 mg q.i.d. (n = 10) 737 (327) 91 (46)
300 mg q.i.d. (n = 10) 1571 (808) 234 (123)
A similar pattern was found for Cmax despite consid-
erable interpatient variability. Details are summarized
in Table 6.
Those patients who required a dose reduction dur-
ing the study tended to be in the b.i.d. treatment
group. There was no clear correlation, however, be-
tween plasma concentrations and the nature, severity
or time of onset of the adverse events reported during
the study.
Plasma concentrations of concomitant carbamazepine
and phenytoin
Plasma concentrations were evaluated in 29 patients
taking concomitant carbamazepine. Baseline plasma
concentrations of carbamazepine in remacemide hy-
drochloride treated patients varied widely at study
entry, ranging from 4.8 to 14.8 µg ml−1. Both
remacemide hydrochloride treated groups (b.i.d. and
q.i.d.) were associated with statistically significantly
increased carbamazepine plasma concentrations at the
800 mg day−1 dose, whereas the placebo treated
patients were not. Increased plasma carbamazepine
concentrations were also associated with remacemide
hydrochloride at 600 mg day−1, compared with
placebo, but were not statistically significant.
Clinically significant increases (defined as >30%)
in carbamazepine plasma concentrations were
recorded in 16 of the 20 patients treated with
remacemide hydrochloride and carbamazepine. The
greatest individual percentage increase in plasma car-
bamazepine recorded was 106%. A trend was apparent
where increasing doses of remacemide hydrochlo-
ride resulted in correspondingly higher plasma carba-
mazepine concentrations. The sample size, however,
was too small to provide the basis for a formal sta-
tistical correlation analysis. In five remacemide hy-
drochloride treated patients the dose of concomitant
carbamazepine was reduced due to symptoms of car-
bamazepine toxicity.
In the placebo treated group, carbamazepine plasma
concentrations for most patients (two exceptions) re-
mained within ±30% of the mean baseline value
(9.9 µg ml−1). Carbamazepine dose adjustments were
necessary for two of these patients during the study:
one patient received an increased dose of carba-
mazepine from 600 to 800 mg day−1, and one patient
was down-titrated from 1000 to 900 mg day−1 due to
symptoms of carbamazepine toxicity.
Analysis of concomitant phenytoin plasma concen-
trations from 17 patients showed greater variation than
with carbamazepine. No significant differences be-
tween the three treatment groups were detected, al-
though the analysis was based on very small patient
numbers. In the 10 patients who received remacemide
hydrochloride and concomitant phenytoin, seven had
plasma phenytoin concentrations ≥50% higher than
baseline. Phenytoin dose reductions were required
by two patients treated with remacemide hydrochlo-
ride compared with no phenytoin adjustments in the
placebo group.
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Table 6: Cmax concentrations for remacemide and desglycinyl metabolite.
Remacemide HCl n Remacemide mean Desglycinyl mean
dose regimen Cmax (range) ng ml−1 Cmax (range) ng ml−1
300 mg b.i.d. 11 785 (156–1602) 66 (21–150)
600 mg b.i.d. 5 1416 (673–2136) 87 (54–128)
150 mg q.i.d. 10 394 (108–826) 30 (13–51)
300 mg q.i.d. 10 796 (238–1695) 78 (35–117)
Table 7: Analysis of median seizure frequency (all seizures) by dose of treatment.
Baseline Difference from baseline
400 mg 600 mg 800 mg 1200 mg Dose-titration Follow-up
Remacemide (b.i.d.) 2.5 −0.5 0.0 0.0 −1.0 −1.0 1.0
Remacemide (q.i.d.) 1.0 0.0 0.0 1.0 0.0 1.0 0.0
Placebo 2.0 2.0 2.0 2.0 1.0 2.0 3.5
Kruskal–Wallis statistic (df.) 0.85 (2) 5.79 (2) 3.55 (2) 2.88 (2) 1.96 (2) 4.07 (2) 4.33 (2)
P-Value 0.65 0.055 0.17 0.24 0.37 0.13 0.11
Efficacy assessment
This study was primarily a safety study. Efficacy
assessments based on investigation of changes in
patients’ seizure frequency and type of seizure
experienced were included as secondary variables.
There were no statistically significant differences
among the three treatment groups in total seizure fre-
quency. Patients in the two remacemide hydrochlo-
ride treatment groups, however, had a consistently
lower median seizure frequency than placebo treated
patients (Table 7). This difference narrowly failed to
reach 5% significance at the remacemide hydrochlo-
ride 400 mg day−1 dosing phase compared with
placebo treatment.
No patient experienced a change in seizure type
during the study; there were no statistically significant
differences among the three treatment groups when
the data relating to individual seizure types were ex-
amined.
Two patients, both receiving remacemide hy-
drochloride, experienced clinically relevant increases
in seizure frequency during the study: one experienced
an increase in seizure frequency which was attributed
by the investigator to a reduction in phenytoin dose.
This patient had reported symptoms of phenytoin tox-
icity earlier in the study and the dose of concomitant
phenytoin had been reduced. The second patient had
an increase in seizures during the withdrawal phase.
DISCUSSION
This study established that remacemide hydrochloride
was generally well tolerated in ascending q.i.d. doses
to 1200 mg day−1 and b.i.d. doses to 800 mg day−1, as
adjunctive therapy to either carbamazepine or pheny-
toin. On the basis of the clinical observations and
safety data provided by this study, it is recommended
that future efficacy or definitive dose ranging stud-
ies adopt adjunctive doses of 800 mg day−1 b.i.d. or
1200 mg day−1 q.i.d.
Four patients were withdrawn from the study due
to adverse events. Of the three withdrawn patients
treated with remacemide hydrochloride, two with-
drawals were considered by the investigator to be un-
related to the study treatment. These events were dys-
phagia resulting from choking on a piece of food and
granulocytopenia; the granulocytopenia was present at
baseline and the patient had been entered in error. The
third remacemide hydrochloride treated patient who
withdrew due to an adverse event experienced nausea
which was considered by the investigator to be possi-
bly related to study treatment.
Of the seven adverse events classified as serious,
only one event, a seizure during the withdrawal phase,
was considered by the investigator to be possibly re-
lated to the study treatment. Analysis of the non-
serious adverse events revealed that patients treated
with remacemide hydrochloride experienced more
CNS and gastrointestinal events than placebo treated
patients. The level of reporting of these adverse
events escalated with increasing doses of remacemide
hydrochloride and as the plasma concentrations of
remacemide and the desglycinyl metabolite increased.
Those patients who required a dose reduction
of remacemide hydrochloride had the highest peak
plasma concentrations of remacemide and desg-
lycinyl metabolite. Despite large interpatient variabil-
ity, remacemide and its desglycinyl metabolite fol-
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lowed predictable pharmacokinetics across the dose
range and regimens evaluated in this study. Dose re-
duction was a more frequent requirement in the b.i.d.
group than in the q.i.d. group.
Neuropsychological testing did not reveal any con-
sistent effects of remacemide hydrochloride on cogni-
tive or psychomotor functions. Physical examination,
vital signs and neurological tests were also clinically
unremarkable during the study and at follow-up.
The plasma concentrations of concomitant carba-
mazepine and phenytoin increased to a clinically sig-
nificant, but variable, extent in the presence of adjunc-
tive remacemide hydrochloride treatment. This inter-
action probably contributed to the reported adverse
event profile in the study. Diplopia, in most cases,
was attributed by investigators to concomitant carba-
mazepine.
This study was not powered to assess the effects of
remacemide hydrochloride on seizure activity. How-
ever, fewer seizures were seen in the remacemide
hydrochloride treatment groups compared with
placebo, although a statistically significant, overall
difference was not achieved among these groups. No
adverse effects on seizure frequency or type were ob-
served in any of the remacemide hydrochloride treated
patients.
CONCLUSIONS
Maximum well tolerated daily dosing regimens
(300 mg q.i.d. and 400 mg b.i.d.) for adjunc-
tive remacemide hydrochloride were determined for
further evaluation in longer term efficacy and safety
studies. Carbamazepine and phenytoin should be
monitored when co-administered with remacemide
hydrochloride in future trials. Such precautionary
measures will help prevent incorrectly attributing ef-
ficacy or toxicity to remacemide hydrochloride when
elevated plasma concentrations of concomitant AEDs
are a confounding factor. Remacemide hydrochloride,
in common with other anticonvulsant drugs, should be
withdrawn gradually to prevent the possibility of re-
bound seizures occurring.
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